800-331-6634

December, 2017

Gene Therapy Approved by the FDA

By editor
December 22, 2017

Mid Atlantic Retina is pleased that the FDA has approved gene therapy, voretigene (Luxturna), for very specific uncommon genetic retinal diseases, caused by mutations in the gene RPE65 which may cause a form of Leber Congenital Amaurosis or retinitis pigmentosa.  These disorders cause severe loss of vision starting at birth or in early childhood.  Not...  read more


2017 Publications

By editor
December 21, 2017

Devon H. Ghodasram, Allen C. Ho, K. Thiran Jayasundera, David N. Zacks. Retinal Prostheses: Clinical Outcomes and Potential Complications. Essentials in Ophthalmology 2017.   Allen C. Ho, Namrata Saroj, Keith Baker, Robert Vitti, Alyson J. Berliner, Desmond Thompson, Daniel B. Roth.  Impact of Baseline Characteristics on Treatment Response to Intravitreal Aflibercept Injection for Wet Age-Related Macular Degeneration. Ophthalmology Retina 2017. Khan MA,...  read more


Wills Eye Hospital Retina Update 2017

By editor
December 12, 2017

Dr Allen Ho & Dr Michael Klufas were the program chairs for Wills Eye Hospital Retina Update the first week of December 2017. The program covered a broad range of subjects from the latest updates in medical and surgical retina care, including emerging opportunities in telemedicine and new vitreoretinal surgical platforms including ultrasonic vitrectomy, culminating...  read more